PHARMIA, INC. (“PHARMIA”) is focused on the production, marketing, and sales of life-saving drugs which are either “at risk” of being discontinued or in chronic short supply in the United States and Europe. Drugs referred to as “at risk” are those that are not considered highly profitable by the leading pharmaceutical manufacturers’ but are still essential in the treatment of life-threatening diseases. In this latter respect, PHARMIA is primarily focused on a portfolio of products to treat cancer and infectious diseases, and shortages of drugs caused by the coronavirus pandemic.

We will continually build on our promise and pledge to deliver safe, effective, and affordable FDA-approved pharmaceuticals and biotechnology products to meet our customers’ needs and to ensure that patients have access to high-quality medicines when they need it.

Our confidence in the ability to execute our strategic plan and play a key role in the pharmaceutical marketplace is underscored by the dedication of our employees and their commitment to excellence in science, manufacturing, quality control, regulatory compliance, safe and effective medicines, and customer satisfaction.

PHARMIA’s mission is critical to the health and safety of at risk patients in the United States, Canada, and in Europe and the Middle East. PHARMIA’s success will result in lives being saved and critical medicines becoming more affordable.

Our business philosophy and growth strategy are built on a commitment to excellence through continuous improvement of our company, and respect for our customers, employees, and community.

Always Forward-Looking

Founded in January, 2020, by a group of caring physicians, pharmacists, drug delivery scientists, and pharmaceutical executives, PHARMIA is becoming a trusted leader in generic drugs and biosimilar biologics in Europe, and in the US and Canada.

PHARMIA is a private, specialty pharmaceutical company focusing on the development, marketing, and sales of essential, life-saving drugs with a focus on the emergency drug shortages we are experiencing in the oncology and the infectious disease treatment areas. Even when supplies by manufacturers of some of these products are obtained, supplies are often sporadic or the products are of unacceptable quality.  In addressing these areas of need, PHARMIA’s team is driven by the conviction that these shortages and lack of quality present significant risks to the lives and well-being of patients.

The U.S. FDA has identified over 163 drugs and biologics like insulin that are experiencing drug shortages resulting in rationing of these drugs – in the US and worldwide. Most of these shortages are in sterile injectable drugs, and a high majority of them are in the cancer treatment and infectious diseases treatment areas. Most of the antimicrobial drugs and many drugs used to treat the side effects of chemotherapy experiencing shortages are administered by mouth (oral). The drug companies are discontinuing manufacturing efforts for older drugs and closing manufacturing facilities because the annual revenue derived from the generic drugs are only $50-$100 million per year. Drug companies are in business to make money and maximize their bottom line, so if the factory used to make a drug bringing in $5 billion/year has the same operating cost as the factory making a drug bringing in $50 million/year, therefore they are going to convert the factory to make the $5 billion/year drug. Sometimes, drug companies outsource manufacturing and use a third party called a contract manufacturing organization or “CMO”, typically outside the U.S. and many times outside of Europe, to make the product, but CMOs can run into FDA regulatory, factory, supply, and logistics issues as well. We obtain our products from FDA-qualified sources in Europe, Canada, and the US.

We have reached a crisis-state in the drug supply-chain in medicine. Most of the drug shortages are for older drugs that are, however, still the mainstay of medicine – drugs like penicillin and aminoglycoside antibiotics and cancer treatment drugs like vincristine and doxorubicin are still of critical need. There are 12 or more anti-cancer drugs experiencing shortages and only a single manufacturer of these agents is in operation. Cancer is treated with 3 or more anti-cancer drugs used together, and when one or more of the drugs is absent, the therapy is far inferior and does not work well.  This is true of cancer therapy and infectious disease therapeutics. When other drugs are substituted instead, the dose and toxic side effects are not known. What if this was your child or family member, and the doctors tell you that you are not getting a proven-effective regimen – you are not getting the standard of care. No one can help!

Our Story